Aesthetic condition change related to patient's opinion · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm)
1 finding from 1 review
Occurrence of adverse effects or postoperative complications · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm)
1 finding from 1 review
Aesthetic condition change related to patient's opinion · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm)
The review found no eligible studies for this question.
1 finding from 1 review
Sites with complete root coverage · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm)
GTR rm + CAF showed no clear difference in sites with complete root coverage compared with SCTG + CAF (low certainty).
1 finding from 1 review
Attachment change · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm)
XCM + CAF showed no clear difference in clinical attachment level change compared with CAF (low certainty).
1 finding from 1 review
Occurrence of adverse effects or postoperative complications · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm)
1 finding from 1 review
Keratinized tissue change · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm)
It is very uncertain whether GTR rm + CAF changes keratinized tissue change compared with SCTG + CAF (very low certainty).
1 finding from 1 review
Change in gingival recession (REC) · Adult patients with single (localised) recession-type defects (Miller Class I/II, at least 3 mm)
It is very uncertain whether EMP + CAF changes gingival recession change compared with SCTG + CAF (very low certainty).
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Duration of episodes · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in mean duration of episodes compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Total ulcer burden · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Kilic 2009 (interferon-alpha lozenges 1000 IU or 2000 IU vs placebo, 84 patients; high risk of selective reporting): the data presented did not allow analysis; authors reported no statistically significant difference…
1 study · 84 participants
GRADE not reported
Quality of life · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Episode duration associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Positive response (not defined) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Triamcinolone acetonide 0.1% ointment (topical) led to higher positive response (not defined) compared with phenytoin syrup mouthwash (30 mg in 5 mL); GRADE not reported.
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Total number of oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Colchicine (systemic; 0.5 mg weight-adjusted daily) showed no clear difference in total number of oral ulcers compared with placebo (moderate certainty).
1 finding from 1 review
Pain associated with oral ulcers · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Time to complete healing · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in healing time compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Number of episodes · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in number of episodes compared with placebo suspension; GRADE not reported.
1 finding from 1 review
Pain (0-3 scale) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
Sucralfate suspension (topical) showed no clear difference in pain (0-3 scale) compared with placebo suspension; GRADE not reported.
1 finding from 1 review